Renal angina: an emerging paradigm to identify children at risk for acute kidney injury by Basu, Rajit K. et al.
EDUCATIONAL REVIEW
Renal angina: an emerging paradigm to identify children
at risk for acute kidney injury
Rajit K. Basu & Lakhmir S. Chawla &
Derek S. Wheeler & Stuart L. Goldstein
Received: 2 August 2011 /Revised: 12 September 2011 /Accepted: 13 September 2011 /Published online: 20 October 2011
# IPNA 2011
Abstract Acute kidney injury (AKI) leads to high rates of
morbidityandindependentlyincreasesmortalityrisk.Therapy
for AKI is likely limited by the inability to reliably diagnose
AKI in its early stages, and, importantly, small changes in
serum creatinine may be associated with poor outcomes and
severe AKI. Whereas AKI biomarker research seeks to
identify more sensitive and timely indices of kidney dysfunc-
tion, AKI lacks physical signs and symptoms to trigger
biomarker assessment in at-risk patients, limiting biomarker
efficacy. Accurate models of AKI prediction are unavailable.
Severity of illness (SOI) scoring systems and organ dysfunc-
tion scores (OD), which stratify patients by prediction of
mortality risk, are AKI reactive, not predictive. Kidney-
specific severity scores do not account for AKI progression,
and stratification models of AKI severity are not predictive of
AKI.Thus,thereisaneedforakidneyscoringsystemthatcan
help predict the development of AKI. This review highlights
the concept of renal angina, a combination of patient risk
factors and subtle AKI, as a methodology to predict AKI
progression. Fulfillment of renal angina criteria will improve
the efficiency of AKI prediction by biomarkers, in turn
expediting early therapy and assisting in creation of AKI-
predictive scoring systems.
Keywords Renal angina.Acute kidney injury.Scoring
systems
Introduction
Acute kidney injury (AKI) is a significant problem in critical
illness. Approximately 5–6% of all hospitalized adults and
10% of children suffer from varying degrees of AKI [1]. AKI
is known to worsen mortality rates, increase duration of
mechanical ventilation, and prolong hospital stays in critically
ill adults and children [2, 3]. The presence of AKI in critical
illness occurs at a rate of 10–15% and carries a 50% mortality
rate in children requiring dialysis [4–6]. AKI survivors are
also at risk for progression to chronic kidney disease (CKD)
[7]. Cross-talk between the kidney and other vital organs has
also been demonstrated to harbor deleterious consequences
on end organ function and in-hospital morbidity and mortality
rates [8, 9], suggesting that AKI-associated mortality is not
solely secondary to standard sequelae (e.g., hyperkalemia,
acidosis, or uremia). Consistently effective AKI therapy to
prevent or limit the disease intensity is lacking, potentially
due to delayed recognition of existing and/or ongoing injury.
AKI diagnosis is traditionally dependent on changes in serum
creatinine (SCr), a marker with limitations involving time,
body habitus, sex, age, steady-state measurement, and patient
condition. Primarily due to the lag in the rise of SCr, the
diagnosis of AKI is often delayed, which creates a significant
barrier to effective early intervention. Notably, small increases
in SCr (0.3 mg/dl) may reflect significant kidney damage and
is associated with poor patient outcomes [10, 11]. As a result,
an intensive research effort has been expended to identify
novel AKI biomarkers to determine therapy to be instituted
prior to a rise in SCr.
R. K. Basu:D. S. Wheeler:S. L. Goldstein
Center for Acute Care Nephrology, Cincinnati Children’s Hospital
Medical Center, Cincinnati Children’s Research Foundation,
Department of Pediatrics,
University of Cincinnati College of Medicine,
Cincinnati, OH, USA
L. S. Chawla
George Washington Medical Center,
Washington, DC, USA
R. K. Basu (*)
Division of Critical Care Medicine-MLC 2005,
Cincinnati Children’s Hospital Medical Center,
3333 Burnet Avenue,
Cincinnati, OH 45229, USA
e-mail: Rajit.basu@cchmc.org
Pediatr Nephrol (2012) 27:1067–1078
DOI 10.1007/s00467-011-2024-5AKI researchers have termed the effort to identify AKI
biomarkers as a quest for the “renal troponin” equivalent.
Treatment for acute myocardial infarction (MI) was trans-
formed by the use of troponin I measurements in patients
with signs and symptoms of a cardiac angina. Sensitivity
and specificity of troponin elevations and electrocardio-
graphic changes for MI have allowed practitioners to
institute early and life-saving therapy. However, whereas
the novel AKI biomarkers recently discovered may serve
well as a renal troponin equivalent, AKI lacks an important
parallel to MI. Simply put, AKI does not hurt. Thus,
whereas many different AKI biomarkers can be used across
a broad swath of critically ill patients, their ability to
improve patient care and outcomes may be limited by the
relatively nonspecific manner in which they are tested [12].
In order to optimize the utility of AKI biomarkers,
screening systems are needed to identify patients who are
at high risk of developing AKI.
Scoring systems are important to epidemiologic study in
critical illness. These scoring systems [severity of illness
(SOI), organ-specific illness scores (OD), and AKI stratifica-
tion scores] provide objective SOI information, allowing
comparisons between therapies, units, and hospitals by
juxtaposing expected versus observed outcomes. However,
the scoring systems are broad-based population comparisons;
individualpatientriskofeithermortalityororganfailureisnot
well assessed. Collectively, these scores, even those that are
kidney centric, are reactive to existing AKI and predictive of
neither AKI nor its severity. Given the remarkably deleterious
contribution of AKI to morbidity and mortality in critical
illness [2, 13], a kidney-injury screening system predictive of
AKI severity and disease progression is needed.
In this educational review, we present our recently
proposed empiric concept of renal angina (RA), a methodol-
ogy to enhance AKI prediction [12] to guide AKI biomarker
assessment. We provide descriptive overviews of the existing
scoring systems for critical illness, kidney-specific severity
scoring systems, and kidney injury stratification scores, all of
which have limited ability to predict AKI. We highlight the
need for improvement in AKI biomarker efficiency. The
description of RA is then used to demonstrate that the
diagnosis of AKI may be made in more real time by
expediting AKI-biomarker efficiency and making the pre-
diction of AKI progression more possible
The necessity of early AKI prediction
AKI increases overall mortality rates, independent of
disease severity. AKI is an independent risk factor for
mortality, with odds ratios (ORs) as high as 4.8, and
independently increases hospital costs, length of stay, and
ventilator days [2, 13–15]. In a study of nearly 4,000
critically ill children, AKI increased mortality rates and
lengthened intensive care unit (ICU) stay fourfold [16].
AKI increases mortality rates in adults and children with
multiorgan failure, hematopoietic stem-cell or solid-organ
transplant, extracorporeal membrane oxygenation (ECMO),
or acute respiratory distress syndrome (ARDS) anywhere
from 10% to 57.1% [17–19]. AKI carries a high risk of
death in children independent of illness severity [5]. AKI
occurs in between 2.7% and 28% of children following
cardiopulmonary bypass (CPB) and carries a notable
increased morbidity risk, including longer duration of
mechanical ventilation and hospital stay [20, 21], and
higher risk of mortality [22]. For these children, a creatinine
rise of ≥25% is a significant risk factor for increased length
of stay and mechanical ventilation, but even a small initial
rise in creatinine leads to an increased risk of subsequently
developing AKI [11]. Finally, at 3- to 5-year follow-up, 40–
50% of pediatric patients with AKI showed signs of chronic
renal insufficiency [23]. Collectively, these studies strongly
suggest that AKI represents a serious burden to the
pediatric patient population and to the health care system
at large.
Effective therapeutic measures for AKI are lacking.
Managing AKI is segmented into optimization of renal
perfusion pressure through preload or vasopressor therapy,
treating oxidative and inflammatory injury, and preventing or
reducing fluid overload (FO) [24–26]. None of these
measures, however, have proven effective at ameliorating
AKI. Augmentation of renal perfusion using volume modi-
fication and vasopressor support has not been shown to
improve mortality rates in patients with AKI. Neither
dopamine [27] nor fenoldopam lessen their risk of mortality
[28]. Therapy for oxidative and inflammatory kidney injury
is largely speculative and has yet to be demonstrated as
efficacious in large studies [29]. The use of renal replacement
therapy (RRT) for inflammatory mediators in AKI is not
globally supported [30]. Notably, positive fluid balance has a
direct correlation with mortality in adults with AKI [31]. The
Prospective Pediatric Continuous Renal Replacement Thera-
py Registry Group (ppCRRT) repeatedly demonstrated in
retrospective studies that increased fluid administration is
independently associated with mortality in children started on
CRRT [32, 33]. Interestingly, in the sum of AKI management
literature, proven and reliable therapies for existing AKI or
for halting the progression of AKI from mild to severe, do
not exist. The state of the art for AKI therapy is preventative
measures aimed at maintaining adequate renal perfusion
pressure, avoiding nephrotoxic agents, treating sepsis, limit-
ing hypoxia, and ensuring adequate nutrition [24, 25]. All of
these data beg the question: Why are all of these therapies
seemingly ineffective?
Delayed recognition likely contributes greatly to the
poor outcome. At diagnosis, AKI has often progressed to a
state of damage that may not be amenable to acute
1068 Pediatr Nephrol (2012) 27:1067–1078intervention. This paradigm has been created by outdated
detection modalities based on creatinine and urine output,
which have limitations hindering early diagnosis. As even
small elevations in SCr are reflective of significant kidney
damage, creatinine is clearly a late marker of AKI [10, 11].
As is discussed later, appreciating the contribution of AKI
to mortality is evident in the evolution of SOI and OD
scores over time. The increasing weighted contribution of
AKI to the overall scores mirrors abundant clinical
evidence of the impact of AKI; patients are now recognized
as dying from and not just with AKI [34, 35]. AKI
biomarker research emphasizes the limitations in creatinine
as a marker and has aggressively sought out new indices of
AKI [36–40]. Proper use and analysis of such biomarkers
would allow for earlier intervention, potentially leading to
amelioration, or possibly prevention, of AKI progression to
overt kidney failure and the associated extrarenal sequelae
of host morbidity and mortality.
Severity of Illness scores do not adequately predict AKI
SOI scores are used to characterize and stratify adult and
pediatric critical illness. The initial SOI systems were
developed to benchmark, or compare, critical care units
against one another, to monitor resource use, evaluate
therapies, and improve quality assessment [41, 42]. They
were not intended to predict SOI in individual patients but,
rather, to group patients together in strata of illness, which
would allow group-wide mortality or SOI prediction.
Iteration of SOI scores reflect adjustments made over time
to weight variables of illness for their retrospectively
appreciated effects on mortality rates. For example, the
weighted contribution of AKI to the SOI score (and thus the
prediction of mortality) has increased in all iterations of all
SOI scores reported to date. SOI scores can be broken
down into three main categories: admission, outcome-
prediction scores, and admission organ-failure scores.
Interestingly, neither category adequately predicts progres-
sion of individual organ failure (i.e., kidney) but, rather,
treats the contribution from AKI to the SOI scores as a
binary variable (present or absent) (Tables 1 and 2).
The admission SOI outcome prediction scores do not
offer prognostication. These survival prediction models
were devised to provide an indication of the risk of death of
groups of ICU patients. Also, these scores do not generally
consider SOI related to organ dysfunction after the first 24–
36 h. Illness in the ICU is commonly an aggregate
consequence of progressive organ dysfunction that occurs
down a continuum. Further, wide variations exist for the
mortality rate predicted in groups of patients with AKI [43],
potentially due to limited sampling of AKI patients. The
major adult SOI outcome prediction models are: The Acute
Physiology and Chronic Health Evaluation (APACHE), the
Simplified Acute Physiology (SAPS), and the Mortality
Probability Model (MPM). APACHE II [44] (Table 1) is the
most widely used SOI for adults. Interestingly, comparison
of sequential iterations of the APACHE II and III scores
illustrates the increasing weight given to AKI (point
increase for elevated creatinine and inclusion of points for
oliguria and azotemia: a smaller increase in creatinine was
required for points, and those points contributed a higher
percentage toward overall mortality rates (Table 1). SAPS
scores, as with those of APACHE, cannot be used to track
disease progression [45]. The MPM models (not depicted)
use a binary system (disease absent or present) [46, 47].
The pediatric SOI models are the Pediatric Risk of
Mortality (PRISM) and the Pediatric Index of Mortality
(PIM). The initial version of PRISM did not include any
contribution to illness from kidney disease [48]. Subsequent
versions of PRISM accounted for AKI and have led to the
most recent version, PRISM III [49]; however, it is notable
that the weighted contribution of severe AKI (SCr≥200%
for selected age) is the same as a serum glucose of 201, a
pH of 7.28, or a platelet count of 200,000. This relatively
low estimation of the contribution of AKI to mortality is
likely explained by the date of PRISM III publication
(1996) before the onslaught of literature noting the
tremendously deleterious impact of AKI on critical illness.
The PIM score has criticisms, including selection and
timing biases [50]. In summary, besides often being
cumbersome to calculate and not always being available
in the public domain (e.g., APACHE III, PRISM III),
APACHE, SAPS, and PRISM, the major SOI scores, have
been useful in critical care units for comparison of mortality
prediction based on illness severity, but none can be used to
predict AKI progression.
Organ dysfunction scores do not adequately predict AKI
OD scores were developed to describe but not predict the
degree of organ dysfunction. The key difference between
the OD and SOI scores is that specific OD is assessed over
time and severity rather than as a snapshot in isolation. The
primary OD scores are the Multiple Organ Dysfunction
Score (MODS), the Logistic Organ Dysfunction Score
(LODS), and the Sequential Organ Failure Assessment
(SOFA) (Table 2). The SOFA [51] scores organ injury
independent of therapy and accounts for escalating AKI
severity but does not function as a predictive tool for
progression. MODS incorporates the worst parameter of
OD for a patient’s entire ICU stay and also does not offer a
prediction for development of kidney injury. The PELOD
score is the pediatric-organ-specific injury score [52] that
has been validated in pediatric intensive care units (PICUs)
in Europe and Canada. Patients with high PELOD scores
and increased number of ODs have the highest probability
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Pediatr Nephrol (2012) 27:1067–1078 1071of death [53]. Additionally, each organ system accounted
for in the PELOD score has been independently associated
with increased mortality risk. However, the contribution of
AKI to the PELOD score does not enable a practitioner to
predict progression and, as Table 2 illustrates, this contri-
bution, while significant, is only based on a present/absent
dichotomization. In summary, whereas OD scores are
intended to assess disease severity based on specific OD
and can be assessed on a continual basis, they do not allow
for study of the time course of OD. OD scores on day X do
not predict the degree of OD on day X+2”or X+3 for
individual organs. Given the contribution of specific OD to
critical illnesses, such as AKI, having an organ-specific
scoring system that would allow prediction of progression
would be highly useful for the bedside practitioner.
Kidney-specific severity scores do not predict AKI
Kidney-specificseverityscoresareusedtoanalyzeriskfactors
for mortality in patients with existing kidney failure. As they
are complex and not facile to calculate at the bedside, kidney-
specific severity scores are used by kidney-disease epidemi-
ologists to analyze the effect of comorbidities on mortality in
patients withAKI (Tables 3 and 4). Table 3 demonstrates that
inclusion criteria for each scoring system require a patient’s
SCr to be significantly elevated. Table 4 describes numerous
Table 2 Organ dysfunction scores
System CV Resp Heme GCS Hepatic Kidney
SOFA Dopa>15, Norepi>0.1=4 P/F : <100=4 Platelets (103/mm3): <20=4 <6=4 Bili (mg/dl): >12=4 Creatinine (mg/dl):>5=4
Dopa>5, Norepi 0–0.1=3 <200=3 <50=3 6–9=3 6–12=3 3.5–5=3
Dopa<5, Dobutamine=2 <300=2 <100=2 10–12=2 2–6=2 2–3.5=2
MAP<70=1 <400=1 <150=1 13–14=1 1.2–2=1 1.2–2=1
S/F: <67=4 UOP (ml/day): <200=4
67–141=3 <500=3
142–220=2
221–301=1
MODS PAR >30=4 P/F : <75=4 Platelet: <20=4 < 6=4 Bili: >240=4
aCreatinine: >500=4
21–30=3 76–150=3 21–50=3 7–9=3 121–240=3 351–500=3
15–20=2 151 – 225=2 51–80=2 10–12=2 61–120=2 201–350=2
10–15=1 226 – 300=1 81–120=1 13–14=1 21–60=1 101–200=1
PELOD HR: P/F: <70=10 WBC: <1.5=10 3=20 ALT>950=1 Creatinine
<12 years >195=10 pCO2: >90=10 1.5–4.4=1 4–6 =10 INR>1.4=1 <7 days >1.59=10
>12 years >150=10 MV=1 Platelet: <35=1 7–11=1 Pupils=10 7 days – 1 year >0.62=10
SBP: PTT>60=1 1–12 years >1.13=10
<1 month <35=20 35–65=10 >12 years >1.59=10
1 month–1 year <35=20
35–75=10
1–12 yr <45=20
45–85=10
>12 <55=20
55–95=10
SOFA Sequential Organ Failure Assessment, MODS Multiple Organ Dysfunction Score, PELOD Pediatric Logistic Organ Dysfunction score, CV
cardiovascular, Resp respiration, GCS Glasgow Coma Scale, Dopa dopamine, Norepi norepinephrine, P/F partial pressure of arterial oxygen/fraction
of inspired oxygen, MAP mean arterial pressure, PAR pressure-adjusted heart rate, HR heart rate, RR respiratory rate, pO2 oxygen partial pressure, Art
arterial, HCO3- bicarbonate, HCT hematocrit, WBC white blood cells, Bili bilirubin, UOP urine output, ALT alanine transferase, INR International
Normalized Ratio, BUN blood urea nitrogen, SBP systolic blood pressure, MV mechanical ventilation, PTT partial prothrombin time
aMicromol/liter
Table 3 Definition of acute renal failure (ARF) in kidney-specific
severity scores
Score Creatinine
(mg/dl)
BUN
(mg/dl)
Chronic disease Δ
creatinine (mg/dl)
over baseline
Bullock ≥ 2.5 ≥100 ≥2.5
Liano ≥ 2 Not used Patients not included
Mehta ≥ 2 ≥40 ≥1
SHARF-IIo ≥ 2 Not used ≥50%
PICARD ≥ 0.5 rise in those
with baseline <1.5
Not used ≥1 in those with baseline
>1.5, baseline >5 not
included
BUN blood urea nitrogen, SHARF Stuivenberg Hospital Acute Renal
Failure, PICARD Program to Improve Care in Acute Renal Disease
1072 Pediatr Nephrol (2012) 27:1067–1078logistic and linear regression models derived using variables
from several other organ systems but illustrates the inappli-
cability of bedside use of such scoring models. Kidney-
specific severity scores have several limitations: they were
almost exclusively derived in single centers, they lack
discriminatory ability to predict mortality [supported by
low area under the curve–receiver operating characteristics
(AUC-ROC)] [54], and are inadequate for AKI prediction or
progression modeling. Also, the use of RRT is not included
in the kidney-specific severity scores. This deliberate
exclusion is secondary to the knowledge that a significant
proportion the sickest critically ill patients are not offered
CRRT or are too unstable to be placed on CRRT.
Accordingly, the kidney-specific severity scores offer no
information about AKI disease severity and CRRT use. The
a priori requirement of a marked creatinine elevation for
inclusion in the initial derivation studies eliminates the
possibility of analyzing the effect of AKI progression on
disease severity and mortality. There are no published
kidney-specific severity scores in children. In summary, the
benefits of the kidney-specific severity scores for the bedside
practitioner, especially the pediatric practitioner, are limited,
and none of the scores allow for progressive AKI prediction.
However, the use of these scores has highlighted comorbid-
ities commonly associated with increased mortality risk in
AKI: age, mechanical ventilation, sepsis, and hypotension
with concurrent vasopressor use being the most cited.
Combining these comorbidities with early AKI to predict
AKI progression may be a valuable tool for the pediatric
bedside practitioner but has not as yet been studied.
Stratification scores and AKI
Scores to stratify single-organ disease do not carry
predictive power for disease progression in that particular
organ. For instance, the Glasgow Coma Scale (GCS), used
to assess impaired consciousness in traumatic brain injury,
does not give internal prediction for progression of
neurologic injury. Similarly, the Ranson criteria, devised
to assess pancreatitis, do not predict progression or
resolution of pancreatic injury. To amend the variability
within AKI diagnosis [55], in 2002, the Acute Dialysis
Quality Initiative Group standardized the definition of AKI
using the RIFLE (a mnemonic for three levels of
severity: Risk, Injury, and Failure, and two outcomes,
Loss and End-stage kidney disease) criteria [56]. Based
on glomerular filtration rate (GFR), SCr values, and urine
output plotted against time of admission, RIFLE marks
progressive degrees of injury in both ICU and non-ICU
adult patients. In 2004, the Acute Kidney Injury Network
(AKIN) devised strata to define AKI based on time in
relation to absolute creatinine increase, percentage in-
crease, or documented oliguria, broadening the window
f o rt i m eo fA K Id i a g n o s i sa n dc r e a t i n ga na u t o m a t i c
“failure” designation for any patient placed on RRT [57].
In 2007, the pediatric amendment to RIFLE was adopted
(pRIFLE) [5], which incorporates changes in creatinine
clearance rather than absolute creatinine values. Validation
studies of RIFLE and AKIN in adults [15, 58, 59], RIFLE
in pediatrics [16], and pRIFLE criteria [60–62] have been
published.
Whereas kidney-injury stratification scores describe and
quantify AKI progression, they do not predict AKI (Table 5).
Several large retrospectively studies have described AKI
progression using RIFLE and AKIN, but they do not
describe risk factors for progression or offer a methodology
for predicting that progression. Patients with the RIFLE
subclasses of injury and failure (I and F) have higher
mortality rates than patients without AKI or who are in the
AKI-R (risk) class [63], so the ability to predict AKI
progression would be of great utility to bedside practitioners
[15, 16]. In a confirmatory study of regression models used
to predict progression of in-hospital AKI to CKD, whereas
5,351/11,589 adults admitted for MI or pneumonia demon-
Table 4 Log odds of death or probability of death given acute renal failure (ARF) in kidney-specific severity scores
Score Log odds of death=sum of variables
Bullock (Log) −1.765-0.687 (CP1+.037)+0.822 (CP2+0.1)+1.053 ([pulmonary complications]−.087)+0.05 (age 61.1)+0.7
([jaundice]+.143)+0.608 ([CV complications]-.247)+0.365 ([hypercatabolism]+.0303)
Liano (Prob) 0.32 (age in decades) – 0.086 (male) - 0.109 (nephrotoxic)+0.109 (oliguric)+0.116 (hypotensive)+0.122
(jaundice)+0.15 (coma) −0.154 (conscious)+0.182 (assisted ventilation)+0.210
Mehta 0.17 (age)+0.8605 (male)+0.0144 (BUN) –0.3398 (creatinine)+1.2242 (hematologic failure)+1.1183
(liver failure)+0.9637 (respiratory failure)+.0119 (heart rate) –0.4432 (log[UOP]) –0.7207
SHARF-IIo 3 (age in decades)+2.6 (albumin category)+1.3 (prothrombin category)+16.8 (mechanical ventilation)+3.9
(heart failure)+2.8 (bilirubin)+27 (sepsis)+21 (hypotension) –17
PICARD 0.1241 (age in decades) −.2063 (log UOP)+.69 (serum creatinine<2)+0.0828 (BUN per 10)+0.4811
(liver failure)+0.58 (ARDS)+0.5074 (platelet count<150)+0.4803 (sepsis) –1.2563
SHARF Stuivenberg Hospital Acute Renal Failure, PICARD Program to Improve Care in Acute Renal Disease, Anuria CP1=0, CP2=1,
Nonoliguria CP1=1, CP2=0, CV cardiovascular, BUN blood urea nitrogen, UOP urine output, ARDS acute respiratory distress syndrome
Pediatr Nephrol (2012) 27:1067–1078 1073strated some degree of AKI by RIFLE, models were not
developed to predict progression of AKI severity during the
actual hospital stay [7].Progression from R to I to F in
pediatrics has been described, though in descriptive fashion
and not using methodology that analyzed the risks of
progression [16]. A useful methodology for predicting AKI
progression, which could immediately aid the bedside
clinician, has not adequately been described.
Biomarkers for AKI
AKI researchers have sought novel early, sensitive, and
specific biomarkers for AKI. As depicted in Table 6,a
plethora of biochemical markers are under study in both
serum and urine of ill patients for established AKI and
early detection, prognosis, and association of AKI with
death . A recent review of AKI biomarkers illustrates that
whereas prospective studies have been performed and
several biomarkers perform well for recognition of
established AKI [most notably, cystatin C, neutrophil-
gelatinase-associated lipocalin (NGAL), and interleukin
(IL)-18], very fewdemonstrate reliablediscriminatoryability
for predicting AKI severity (by AUC-ROC) [39]. In fact,
serum NGAL was unable to identify children who would
require RRT, whereas serum cystatin C showed modest
discriminatory ability (AUC 0.76). Similarly, in several
Table 5 Stratification of kidney injury
Scheme Stage Creatinine criteria Urine output criteria
RIFLE R – Risk ↑≥1.5x or ↓GFR≥25% < 0.5 ml/kg/h for 6 h
I – Injury ↑≥2x or ↓GFR≥50% < 0.5 ml/kg/h for 12 h
F – Failure ↑≥3x or [Cr]>350 μmol/L < 0.3 ml/kg/h for 24 h or anuria for 12 h
L – Loss Persistent failure >4 weeks
E – End stage Persistent failure >3 months
Pediatric RIFLE (pRIFLE) R – Risk eCrCl ↓≥25% < 0.5 ml/kg/h for 8 h
I – Injury eCrCl ↓≥50% < 0.5 ml/kg/h for 16 h
F – Failure eCrCl ↓≥75% or eCrCl<35 ml/min/1.73 m
2 < 0.3 ml/kg/h for 24 h or anuria for 12 h
L – Loss Persistent failure >4 weeks
E – End stage Persistent failure >3 months
AKIN Stage 1 ↑≥0.3 mg/dl or ↑ to 150-200% baseline < 0.5 ml/kg/h for 6 h
Stage 2 ↑ to 200-300% baseline < 0.5 ml/kg/h for 12 h
Stage 3 ↑ to ≥300% baseline or ≥4.0 mg/dl with an
acute ↑ of 0.5 mg/dl
< 0.3 ml/kg/h for 24 h or anuria for 12 h
GFR glomerular filtration rate, Cr creatinine, eCrCl estimated creatinine clearance
Table 6 Biomarkers under study for acute kidney injury (AKI)
Time frame Established AKI Early detection Prognosis Death
Serum NGAL NGAL NGAL NGAL
Cystatin C Cystatin C Cystatin C Cystatin C
Carb-Hb Pro-ANP neutrophil-CD11b IL-6, IL-8, IL-10
Urine NGAL NGAL NGAL NGAL
IL-18 IL-18 Cystatin C aprotinin IL-18
GST GST, α-GST α-GST KIM-1
NAG NAG NAG NAG
α-1 microglobulin KIM-1 γ-GT α-1 microglobulin
NHE-з KIM-1 KIM-1
MMP-9 π-GST β-2-microglobulin
MMP-9 GGT
AP LDH
LDH
NGAL neutrophil gelatinase-associated lipocalin, Carb-Hb carbamylated hemoglobin, Pro-ANP pro-atrial natriuretic peptide, IL interleukin,
GST glutathione S-transferase, NAG N-acetyl-glucosamine, γ-GT gamma-glutamyltranspeptidase, MMP matrix metalloproteinase, AP
aminopeptidase, LDH lactate dehydrogenase, KIM-1 kidney injury molecule-1
1074 Pediatr Nephrol (2012) 27:1067–1078studies, urinary biomarkers were ineffective at predicting
AKI progressing to the need for RRT [38, 64]. Neither serum
nor urine biomarkers have impressive statistical performance
in predicting AKI-associated death [65–67]. Additionally,
almost all biomarker studies have analyzed specific bio-
marker levels (plasma or urine) as cutoffs for rule-in/rule-out
analyses (e.g., urine NGAL level 50 ng/ml for AKI in
children post-CPB [68]); interpreting exact biomarker values
for specific AKI-causing disease processes is thoroughly
unexplored. A recent review of biomarker studies performed
in children with AKI demonstrates several truths that temper
the encouraging results to date for AKI diagnosis or
prediction: diagnosis is often based on a SCr change >50%
(which, as stated earlier, may be an overestimate of
significant injury and may contribute to the high sensitivities
reported), cutoff values often sacrifice specificity for high
sensitivity, and nearly all derivation studies have been
performed in extremely high-risk patients (postkidney
transplant or CPB) [69]. Implementation of AKI biomarkers
to the general pediatric population, or even the critically ill
pediatric population, will continue to demonstrate such
statistical bias, and therefore dampen enthusiasm for results,
until a structured methodology for identifying tiers of at-risk
children is developed.
Renal angina: more than risk stratification
Given the limitations of the SOI and AKI classification
systems noted above, we sought to use the available
evidence to formulate a concept of RA to identify critically
ill patients at-risk for AKI [12]. Risk is informed by
baseline and contextual risk factors (e.g., diabetes, high-risk
procedures such as CPB), and evidence of injury (FO,
oliguria, increased SCr). In short, RA is a clinical guide that
identifies patients at high risk for AKI by integrating
baseline, contextual, and clinical evidence of kidney injury.
For example, patients undergoing CPB and bone marrow
transplantation (BMT) are at high risk for AKI, but there is
little utility in measuring biomarkers every 6 h in every
patient every day. Similarly, patients with sub-RIFLE
changes in estimated creatinine clearance (eCrCl) and
increases in FO are at risk for progression to more severe
AKI, but many do not progress. Furthermore, many patients
may present with acutely elevated SCr levels, which may
be easily reversible with hydration (prerenal azotemia or
fluid-responsive AKI). Thus, RA, which combines baseline
and contextual risk factors with various thresholds of
evidence of acute kidney dysfunction, from sub-RIFLE to
RIFLE changes, should improve the prediction of clinically
significant AKI and direct novel biomarker assessment.
More importantly, combining RA with biomarkers should
improve the positive predictive value of biomarkers to
detect AKI development and severity.
RA can be thought of in terms of a simple equation:
Renal AnginaThreshold ¼ Risk of AKI   Evidenceof AKI
Thus, as the AKI risk increases (e.g., BMT patient on
vasopressors and mechanical ventilation), less evidence of
AKI is needed(smallchangesin SCr) to meet the thresholdfor
RA. Conversely, a patient with few risk factors of AKI (a
young child admitted to ICU for bronchiolitis but not
intubated) would require more evidence of AKI in order to
achievetheRAthreshold.Oncepatientsachievethatthreshold,
then the task of the clinician is to rule out AKI using AKI
biomarkers and other clinical investigations. We believe that
this diagnostic framework is consistent with other clinical
syndromes and provides an approach that nonnephrology
clinicians can use. We proposed three strata of risk groups by
tranches (Table 7). As the risk of AKI increases by tranche,
the clinical evidence of kidney injury required to achieve RA
is decreased. Thus, fulfilling pediatric RA criteria is based on
the combination of an initial risk stratification emanating
from the underlying clinical state (ICU admission, BMT, or a
patient receiving invasive mechanical intubation), with early
signs of renal dysfunction (small, sub-RIFLE) changes in
SCr, or positive, or mild degrees of positive, fluid accumu-
lation. Admittedly, the availability and ease of calculating
changes in eCrCl for a given patient is not universal,
especially in pediatric patients without previous illness (and
documented baseline SCr levels). Accordingly, we propose
that absolute changes in SCr may also be used: very high risk
(any change in SCr from baseline for patient of similar age
and size per standard reference values), high risk (change in
Table 7 Pediatric renal angina criteria
Hazard tranche Renal angina threshold
Moderate-risk patients Doubling of SCr
a
Patients admitted to PICU
a OR
eCrCl decrease >50%
OR
ICU fluid overload >15%
High-risk patients Serum Cr increase ≥0.3 mg/dl*
￿ Acute decompensated heart failure OR
￿ Stem-cell-transplant recipient eCrCl decrease 25-50%
OR
ICU fluid overload >10%
Very-high-risk patients Any Serum Cr increase*
Receiving mechanical ventilation
and one or more vasoactive
medications
OR
eCrCl decrease >25%
OR
ICU fluid overload >5%
PICU pediatric intensive care unit, SCr serum creatinine, OR odds
ratio, eCrCl estimated creatinine clearance, ICU intensive care unit
Pediatr Nephrol (2012) 27:1067–1078 1075SCr of at least 0.3 mg/dl), and moderate risk (doubling of
SCr, which would correlate to an estimated decrease in CrCl
of ∼50%). Patients who fulfill features of both the risk
stratification and the associated threshold for clinical signs of
kidney dysfunction are akin to the cardiac angina paradigm to
guide troponin assessment. For instance, troponin would not
be expected to function well for predicting myocardial
ischemia in an otherwise healthy 25-year-old who experi-
enced chest pain after eating a fatty meal. Likewise, troponin
should not be drawn on every 85-year-old seen in an
emergency room, irrespective of the presence of chest pain
just because MIs are more prevalent in older individuals. In
fact, when troponin is tested in critically ill patients without
signs and symptoms of acute coronary syndrome, it loses its
diagnostic capacity.
Thethree-tieredclinicalriskstratificationschemewasbased
on observed AKI rates (defined as pRIFLE-I, or a 50% rise in
SCr) in a number of pediatric epidemiological studies. For all
ICU patients, AKI rates were reported as 4–10% [16, 70],
pediatric BMT recipients had a reported rate of 11–21% [71,
72], and critically ill patients receiving mechanical ventilation
had a reported rate of 50% [5, 60]. We termed these strata
moderate, high, and very high risk, respectively. The tiers
were based on available clinical data with demonstrated risk
for developing AKI. Other patients, such as general oncology
patients, solid-organ transplant recipients, and immunosup-
pressed patients, also carry increased AKI risk, but they were
grouped together in the moderate-risk groups (ICU admis-
sion) for simplicity. With increasing risk strata, thresholds for
the corresponding clinical sign (SCr change or percent fluid
accumulation) to fulfill RA criteria decreases accordingly.
Numerous retrospective pediatric studies demonstrated the
potential negative implication of excessive FO. Based on
aggregate analysis of data and consensus opinion within the
ppCRRT, an estimated 10–15% FO at time of CRRT
initiation is associated with increased risk of mortality. Using
the 10% number as a median, we established initial thresh-
olds for RA FO to reflect standard intervals above and below
based on AKI risk (e.g., 5%, 10%, 15%) [73]. To further
relate RA to the troponin-MI paradigm, if a patient has
diabetes, hypertension, and smokes, the amount of chest pain
or dyspnea required to raise suspicion of acute coronary
syndrome is much less than in a thin patient without any of
these risk factors. Additionally, we designed criteria with the
intent that the negative predictive value should be extremely
high in patients who do not fulfill the RA criteria, thus
precluding capricious biomarker testing/assessment in
patients who will not likely develop AKI.
We must be clear that this point to state that RA as we
have conceived it remains an empiric concept, although we
are actively testing it in our pediatric ICU population. Once
validated and—likely—refined, we hope that RA can serve
to optimize biomarker assessment in critically ill children.
Questions: (answers are provided following the reference
list)
1. Of the following, the recommended therapy for
improving mortality rates of AKI is
a) Optimizing renal perfusion with fluid or vasopressors
b) Optimizing nutrition
c) Early recognition and elimination of ongoing
agents leading to AKI
d) Diuretics
2. Which of the following pediatric illness scores has a
weighted contribution for increasing creatinine values?
a) PELOD
b) PRISM I
c) PRISM III
d) SOFA
e) None of the above
3. Which AKI stratification levels have been demonstrated
to be associated with increased mortality risk in children?
a) pRIFLE R, I, and F
b) pRIFLE I and F
c) AKIN stage 2
d) pRIFLE F only
4. The current incidence of AKI in ventilated pediatric
ICU patients is:
a) <1%
b) 45–55%
c) 11–20%
d) 4–10%
5. To fulfill RA, a mechanically ventilated child on
inotropy requires an eCrCl change or an FO of:
a) Decrease by >50% or FO >15%
b) Decrease by >25%, FO >15%
c) Decrease by >50%, no FO requirement
d) Decrease by >25%, no FO requirement
e) Decrease by >25%, FO >5%
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